Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether an increase in the dose of sorafenib when
given over five instead of 7 days/week, will result in an improvement of the response rate
(degree of shrinkage of your cancer) and an improvement in the length of time that sorafenib
will control your cancer, without causing a significant increase in side effects.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center